Novo Nordisk A/S $NVO Shares Purchased by QV Investors Inc.

QV Investors Inc. boosted its position in Novo Nordisk A/S (NYSE:NVO) by 28.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 369,468 shares of the company’s stock after buying an additional 81,870 shares during the period. Novo Nordisk A/S makes up approximately 1.4% of QV Investors Inc.’s investment portfolio, making the stock its 25th largest holding. QV Investors Inc.’s holdings in Novo Nordisk A/S were worth $17,712,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Godfrey Financial Associates Inc. purchased a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at $25,000. Scarborough Advisors LLC purchased a new position in shares of Novo Nordisk A/S during the first quarter worth $26,000. WealthCollab LLC lifted its position in Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after purchasing an additional 260 shares during the period. Jackson Grant Investment Advisers Inc. acquired a new position in Novo Nordisk A/S during the fourth quarter valued at $29,000. Finally, Quaker Wealth Management LLC boosted its holdings in Novo Nordisk A/S by 186.0% in the fourth quarter. Quaker Wealth Management LLC now owns 615 shares of the company’s stock valued at $31,000 after purchasing an additional 400 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on NVO. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Berenberg Bank set a $47.00 target price on Novo Nordisk A/S in a report on Wednesday. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Finally, Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday. Four investment analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $64.94.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CEO Mike Doustdar said the obesity-drug market will not be “winner-take-all,” arguing that patients’ differing preferences and demand for pills, injectables and other differentiated treatments should support multiple successful players. Reuters article
• Positive Sentiment: Novo’s oral Wegovy appears to be generating strong prescription momentum, offering a potential new growth channel and helping the company compete beyond its injectable portfolio. However, investors are watching whether that momentum can offset Lilly’s faster growth. Zacks article
• Positive Sentiment: Zacks Research upgraded NVO from “strong sell” to “hold,” indicating that the stock’s sharp decline and low earnings multiple may have reduced some downside risk.
• Neutral Sentiment: Novo defended its lawsuit challenging Eli Lilly’s weight-loss advertising, saying competition must be fair. The litigation could protect Novo’s marketing position, but it also highlights the intensity of the competitive battle. CNBC article
• Neutral Sentiment: Novo’s CEO continues to promote a long runway for obesity treatments, citing low overall adoption and potential healthcare-cost benefits. These are long-term opportunities rather than immediate earnings catalysts. Fox Business article
• Negative Sentiment: Eli Lilly’s growing share in both injectable and oral weight-loss drugs is the main concern. Analysts warn that Lilly’s momentum could widen the competitive gap and limit the upside investors had anticipated from the Wegovy pill. Yahoo Finance article
• Negative Sentiment: Berenberg downgraded Novo from “buy” to “hold,” citing expectations that the initial Wegovy-pill upside is already reflected in the stock and valuing the company closer to the broader European pharmaceutical sector.
• Negative Sentiment: Recent analysis also points to flat Wegovy sales, pricing pressure and pipeline setbacks as near-term risks, helping explain why NVO has decreased despite its strong margins and broader cardiometabolic pipeline. Zacks analysis

Novo Nordisk A/S Stock Up 0.8%

NVO stock opened at $46.75 on Friday. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $64.16. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The firm’s fifty day moving average is $47.30 and its 200 day moving average is $44.50. The firm has a market cap of $208.74 billion, a PE ratio of 11.43, a P/E/G ratio of 4.23 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. The business had revenue of $11.98 billion during the quarter. On average, research analysts forecast that Novo Nordisk A/S will post 3.39 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a dividend, which will be paid on Tuesday, August 25th. Investors of record on Monday, August 17th will be issued a $0.5786 dividend. The ex-dividend date of this dividend is Monday, August 17th. This represents a yield of 254.0%. Novo Nordisk A/S’s dividend payout ratio is presently 42.79%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.